

HIV, HCMV and mycobacterial antibody levels: a cross-sectional study in a rural Ugandan cohort

Lisa Stockdale¹, Stephen Nash², Angela Nalwoga^{1,3}, Lorna Gibson², Hannah Painter¹, John Raynes¹, Gershim Asiki^{4,5}, Robert Newton^{3,6,7,*} and Helen Fletcher^{1,*}

¹ Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, UK

² Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, UK

³ Medical Research Council/Uganda Virus Research Institute, Entebbe, Uganda

⁴ African Population and Health Research Center, Nairobi, Kenya

⁵ Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden

⁶ Department of Health Sciences, University of York, York, UK

⁷ International Agency for Research on Cancer, Lyon, France

Abstract

OBJECTIVES A growing evidence base implicates human cytomegalovirus (HCMV) as a risk factor for TB disease. We investigated total IgG and mycobacteria-specific antibodies in a cross-sectional study nested within a rural Ugandan General Population Cohort (GPC), in relation to HIV infection and the magnitude of HCMV IgG response.

METHODS Sera from 2189 individuals (including 27 sputum-positive TB cases) were analysed for antibodies against mycobacteria (Ag85A, PPD, LAM, ESAT6/CFP10) and HCMV, tetanus toxoid (TT) and total IgG.

RESULTS Anti-mycobacterial antibodies increased with age until approximately 20 years, when they plateaued. Higher HCMV exposure (measured by IgG) was associated with lower levels of some anti-mycobacterial antibodies, but no increase in total IgG. HIV infection was associated with a decrease in all anti-mycobacterial antibodies measured and with an increase in total IgG.

CONCLUSIONS The increase in anti-mycobacterial antibodies with age suggests increasing exposure to non-tuberculous mycobacteria (NTM), and to *M.tb* itself. HIV infection is associated with decreased levels of all mycobacterial antibodies studied here, and high levels of HCMV IgG are associated with decreased levels of some mycobacterial antibodies. These findings point towards the importance of humoral immune responses in HIV/TB co-infection and highlight a possible role of HCMV as a risk factor for TB disease.

keywords TB, HIV, HCMV, *Mycobacterium*

Introduction

The role of antibody-mediated immunity in TB has not been fully elucidated (reviewed in [1]). Despite the importance of cell-mediated Th1 responses in TB disease [2, 3], attempts to stimulate this arm of the human immune response by vaccine developers have not translated into protection from disease in human efficacy trials [4, 5], and there may be useful humoral correlates of disease or protection yet to be identified.

A growing evidence base for the importance of antibodies in protection against other intracellular pathogens such as *Listeria monocytogenes* [6] and *Salmonella* spp. [7] has led to renewed interest in humoral responses to

TB and the factors which may affect them. Recent work has suggested a potential protective role of antigen 85A (Ag85A)-specific antibodies in reduced TB disease risk in BCG-vaccinated South African infants [8, 9].

It is known that TB and HIV work synergistically to exacerbate morbidity and mortality in co-infected individuals with respect to both diseases [10]. Epidemiologically, concomitant viral infections other than HIV are known to be associated with poor TB outcomes. In Taiwan Hepatitis C infection was associated with a higher risk of developing active TB disease [11], and in South Africa influenza/TB co-infection was associated with increased mortality [12]. A large TB vaccine trial in South Africa, which investigated correlates of TB disease risk or protection, found an association between CD8 T-cell activation

*These authors contributed equally to this work.

and HCMV response [8] that was linked to an increased risk of TB disease and shorter time to diagnosis [13].

The ubiquitous herpes virus HCMV is known to cause immune activation [14], immune senescence [15], and is a significant factor in immune variation [16]. Recently, our group has reported elevated levels of HCMV IgG among TB patients compared to controls [17]. Despite this, and the findings of some early epidemiologic studies [18, 19], data linking HCMV and TB are sparse.

To investigate mycobacteria-specific antibody levels across ages, and to examine potential effects of HCMV co-infection on antibody levels, this study tested 2187 stored serum samples (of which 27 were active TB cases) from a rural Ugandan cohort for IgG responses to Ag85A, purified protein derivative (PPD), lipoarabino-mannan (LAM) and CFP10/ESAT6, along with IgM responses to Ag85A. These antigens were chosen based on availability, evidence of their potential importance in TB disease from the literature (Ag85A [9], LAM [20, 21], PPD [22]), and specificity to *M.tb* (CFP10/ESAT6 [23]). Seropositivity to HCMV was measured and existing data on HIV, BCG vaccination status, as well as demographic information was matched and investigated for associations. Responses to tetanus toxoid (TT) and total IgG levels were also investigated as control antibodies.

Materials and methods

Study area and design

The General Population Cohort (GPC) is a population-based open cohort study in rural south-western Uganda, administered by the Medical Research Council (MRC) UK in collaboration with the Uganda Virus Research Institute (UVRI) [24]. The cohort comprises a cluster of 25 neighbouring villages with approximately 20 000 residents (52% aged <13 years) from three ethnic groups, the majority (75%) being from the Baganda tribe, the main tribal group in the region. Data are collected through an annual census, questionnaire and serological survey (further details on questions included in the census can be found in a publication by Asiki *et al.* [24]). Demographic information was collected at the same time as the blood samples. Blood specimens were obtained and immediately tested for HIV-1. Samples with inconclusive results were retested. Remaining sera were stored at -80°C . All samples used for this study, except active TB cases, were collected from adults and children in GPC round 22, conducted in 2011. Active TB cases were diagnosed through positive sputum smear microscopy after passive case detection and were sampled from a range of GPC rounds between 1999 and 2014. Sera collected as

close as possible to the time of TB diagnosis were used for this study (between 5 years prior to, and 0.8 years after diagnosis of active TB diagnosis).

Sampling

Individuals were selected for inclusion in this cross-sectional study at random after stratification by age and sex. Due to anticipated high levels of HCMV seropositivity, infants under the age of 5 were oversampled. Individuals were only sampled once and siblings and parent-child pairs were not excluded. The total planned sample size was 2000, plus 10% oversampling. A target of approximately 100 individuals per year of age up to 5 years, 200 individuals aged 6–10, 11–15 and 16–20, 200 in subsequent 10-year intervals up to 60 years and 200 people aged 61 years or over. The sex ratio was approximately equal within each age group (Table 1).

Ethics

Written consent or assent in conjunction with parental/guardian consent for those younger than 18 years were obtained following Uganda National Council of Science and Technology (UNCST) guidelines before all survey procedures [24]. Written consent/assent was also obtained from participants on the use of their clinical records and stored biological samples for research purposes.

Ethical approval for the use of GPC samples for this study was obtained from the UVRI Research and Ethics Committee and from the UNCST, in addition to the London School of Hygiene & Tropical Medicine (LSHTM), London, UK.

Serology: Ag85A, PPD, LAM, CFP10/ESAT6 and TT

Antibody content was measured using ELISA. Experimenters were blind to exposure group for all samples. Testing was conducted at UVRI in Entebbe, Uganda (Ag85A IgG and PPD IgG) and LSHTM, London, UK (CFP10/ESAT6 IgG, Ag85A IgM, LAM IgG and TT IgG). Half volume ELISA plates (Fisher Scientific) were coated overnight at 4°C with sodium carbonate buffer containing 1.5 $\mu\text{g/ml}$ recombinant Ag85A protein (Aeras, USA), 1.5 $\mu\text{g/ml}$ PPD (Lot 051815KA, Aeras, USA), 0.5 $\mu\text{g/ml}$ TT (02/232, NIBSC, UK), 0.5 $\mu\text{g/ml}$ LAM (NR-14848, BEI Resources, VA, USA), 0.25 $\mu\text{g/ml}$ each CFP10 (NR-49425, BEI Resources, VA, USA) and ESAT6 (NR-14868, BEI Resources, VA, USA). Plates and reagents were brought to room temperature and the plate was washed three times with PBS, 5% Tween20 (v/v) (PBST). After blocking with PBS 5% milk (w/v) blocking

Table 1 Characteristics of study participants (HCMV seropositive individuals by age group ($n = 1988$)). Sex, HIV infection, BCG vaccination and TB case prevalence is shown for each age group

Age group (year)	<i>n</i>	Sex (percentage female (number/total))	HIV prevalence, percentage (number/total)	BCG vaccinated, percentage (number/total)	Active TB cases, percentage (number/total)
<1	75	47% (35/75)	4% (3/73)	76% (54/71)	0% (0/75)
1	83	51% (42/83)	1% (1/80)	96% (73/76)	0% (0/83)
2	82	52% (43/82)	1% (1/78)	90% (63/70)	0% (0/82)
3	87	47% (41/87)	1% (1/85)	93% (70/75)	0% (0/87)
4	100	52% (52/100)	0% (0/97)	94% (82/87)	0% (0/100)
5	106	54% (57/106)	1% (1/101)	8% (80/90)	0% (0/106)
6–10	183	47% (86/183)	1% (2/175)	90% (135/150)	0% (0/183)
11–15	192	49% (94/192)	0% (0/187)	81% (125/155)	1% (1/192)
16–20	204	51% (105/204)	1% (3/204)	69% (132/190)	0.5% (1/204)
21–30	216	56% (120/216)	9% (19/216)	70% (128/184)	2% (5/216)
31–40	238	52% (123/238)	13% (31/238)	57% (119/209)	4% (10/238)
41–50	166	45% (74/166)	15% (25/166)	52% (75/145)	4% (6/166)
51–60	109	49% (53/109)	6% (7/109)	53% (52/98)	4% (4/109)
61+	147	46% (68/147)	1% (2/147)	26% (37/144)	0% (0/147)
Total	1988	50% (993/1988)	5% (96/1956)	70% (1225/1744)	1.4% (27/1988)

buffer, duplicate 1:100 test serum, high and low PPD responder controls and plate blanks consisting of assay diluent alone with no serum were added in triplicate. Incubation for 2 h at room temperature and washing with PBST was followed by a one hour incubation with an appropriately diluted peroxidase-conjugated secondary antibody in PBST-5% (IgG, 1:500 dilution of goat anti-human IgG-HRP (04-10-20, KPL, USA); IgM, 1:10 000 dilution of goat anti-human IgM-HRP (Abcam ab97205, RRID: AB_10695942)). After washing with PBST, 50 μ l tetramethylbenzidine (TMB, BD BioSciences, USA) was added to each well. The plate was incubated for 15 min in the dark before the reaction was stopped by adding 50 μ l of 2M Sulphuric Acid (Sigma, USA) to each well. Absorbance was measured at 450 nm within 30 min to obtain optical density (OD), a surrogate marker of antibody titre.

Mean blank values were subtracted from all OD readings, and geometric means of duplicates were used to reduce the effect of skewed distribution. Median levels with interquartile ranges (IQR) are used for graphical representation of antibody levels in Figures 1 and 2.

Total IgG serology

All samples were tested for total IgG content at LSHTM. As above, half volume ELISA plates were coated overnight with mouse anti-human IgG at 0.5 μ g/ml (Abcam ab200699). IgG antibody standards (134.4–8.4 ng/ml) were prepared by diluting purified human IgG (Sigma I4506, RRID:AB_1163606) in PSBT-5% milk and test

sera were diluted 8×10^5 in PBST-5% Milk. Duplicate test samples, controls and blanks were incubated for one hour at 37 °C, and, after washing, samples incubated with peroxidase-conjugated goat anti-human Fc (Abcam ab97225, RRID: AB_10680850) diluted 1/500 with PBST-5% Milk for one hour at room temperature. Plates were developed with TMB, and sulphuric acid was added to stop the reaction. Plates were read at 450 nm and OD measurements converted into g/l by use of the standard curve on each plate.

Serology HCMV

Samples were tested for IgG antibodies against HCMV using a commercial ELISA kit (Novatec Immunodiagnostica GmbH) according to kit instructions (described in [17]).

Statistical analysis

Correlations between each pair of mycobacterial antibody OD levels were conducted using Spearman's rho. Because of the ubiquity of HCMV infection within this population [17], analysis was conducted on the HCMV-seropositive population only.

Individuals seropositive for HCMV IgG were further categorised into three groups according to the tertiles of HCMV antibody concentrations (measured by OD): low, medium and high.

Linear regression was used to determine the association of each antibody response (as continuous dependent

L. Stockdale *et al.* **HIV, HCMV and mycobacterial antibody levels**




Figure 1 Median mycobacterial antibody OD by age group. Vertical lines show IQR for median values for each age group. Total $n = 1988$. OD values rescaled to the percentage of maximum for graphical representation. IQR, interquartile range, OD, optical density.




Figure 2 (a) Median OD levels for TT IgG by sex and age group. (b) Median total IgG (g/L) by age group. Vertical lines show IQR for each median data point. Total $n = 1988$. Figure 2a red lines represent median values for females, blue lines for males. Figure 2(b) shows data for males and females combined. IQR, interquartile range, OD, optical density.

variables) with HCMV IgG tertile and HIV infection (as independent variables with HCMV as a categorical variable), adjusting for age and sex. BCG vaccination status and active TB disease were also included in the regression

model, however as 89% (24/27) of active TB cases had unknown BCG status, it was not possible to include both variables in the same model. The model including TB was preferred, with the model including BCG run as a

comparison to confirm the consistency of the results. BCG vaccination was included in a separate regression analysis using the same model.

Individuals with unknown HIV status were excluded from all regression analyses and individuals with unknown BCG vaccination status were excluded from regression analyses including BCG. To account for evidence of non-linearity of antibody OD with age (likelihood ratio test $P < 0.001$ for all antibodies), a quadratic term for age was included in the regression analyses. Numbers included in each of the regression analyses are shown in Tables 2 and 3.

To account for multiple comparisons, 99% confidence intervals (CIs) are reported and a P value of 0.01 was considered to represent strong evidence to reject the null hypothesis. Due to different dynamic ranges of spectrophotometers used in Uganda and the UK, antibody OD measurements (for mycobacterial antibodies only) were rescaled for graphical representation. This was done by subtracting the minimum value within the range from each value, dividing by the range for that antibody and multiplying by 100; hence Figure 1 shows the percentage of the maximum OD. All analyses were performed on raw data using Stata version 14 (Stata Corporation, College Station, TX, USA). Anonymised participant data are available.

Results

Sera were sampled from 2189 individuals. Total IgG levels could not be determined in 15 instances, likely due to protein degradation. Of the remaining 2174 individuals, 8.6% (186/2174) were HCMV-seronegative and were excluded from analysis. The HCMV-negative population contained no TB cases and 4 HIV-positive individuals. Ninety-eight (53%) were female and the mean age was 14.6 years (range 3 months–95 years).

The remaining 1988 individuals were included in further analyses. The mean age was 23.4 years (range 30 days–100 years) and 50% were female (Table 1). Ninety-eight per cent (1956/1988) of individuals had a conclusive HIV result, and of those, 4.9% (96/1956) were HIV-positive, with the greatest proportion in the 31–50 year age group.

Twenty-seven sputum-confirmed TB cases were included in the study, of whom 63% (17/27) were female and whose mean age was 36 years (range 12–59 years). Only three TB cases had BCG vaccination information and all of those were unvaccinated. All 27 were HCMV-seropositive, with 59% (16/27) having HCMV IgG levels in the upper tertile.

Antibody responses

IgG against Ag85A, PPD, LAM, CFP10/ESAT6 and IgM against Ag85A all increased from birth to approximately 20 years of age, after which OD values reached a plateau. Figure 1 shows median OD for each of the mycobacterial antibody levels by age group. Initial levels in infants under the age of one year range from a median of 4% of maximum OD (0.12 OD) for Ag85A IgM to 12% of maximum OD (0.35 OD) for LAM IgG. Responses to the *M.tb*-specific ESAT6/CFP10 antigens did not show the same rapid increase from birth as responses to other mycobacterial antibodies. The highest 10% of responders in terms of CFP10/ESAT6, being *M.tb* specific antigens, were investigated further and there was no evidence of a difference in proportion of TB cases or HIV positive individuals compared with the lowest 10%.

Univariate analysis showed no differences in mean OD levels by sex. Analysis of correlation showed a high degree of co-linearity between all mycobacterial antibodies ($0.33 > \rho < 0.65$, all $P < 0.001$). OD ranged from 0.002 to 1.793 OD for Ag85A IgG, 0.000 to 1.930 OD for PPD IgG, 0.004 to 2.961 OD for LAM IgG, 0.005 to 2.927 OD for CFP10/ESAT6 IgG and 0.001 to 2.926 OD for Ag85A IgM.

Tetanus toxoid and total IgG levels were investigated as control antibodies (Figure 2). TT vaccination induces high levels of TT IgG and is given at birth and to pregnant females as part of the Uganda immunisation schedule [25]. TT IgG showed high levels of antibody from birth and a clear sex difference with females having higher overall IgG levels ($P < 0.001$, Figure 2a). This difference is driven by females aged between 16 and 50 years (Figure 2a). Total IgG levels increase with age from birth (median 46.2 g/l in infants less than one year of age) to a plateau after 11 years of age (median 69.4 g/l), Figure 2b. Since a univariate analysis of total IgG by sex indicated no difference, data were not separated by sex for this plot.

In a multivariable linear regression model including TB disease status, being HIV-positive was associated with a decrease in all mycobacterial antibody levels studied (magnitude ranged from mean decrease in 0.240 OD (99% CI -0.361 , -0.119) for IgG against Ag85A), to a mean decrease in 0.446 OD (99% CI -0.640 , -0.251) for IgM against Ag85A, all $P < 0.001$, Table 2). Similarly, being in the upper tertile of HCMV IgG response was associated with a decrease in Ag85A, PPD and LAM IgG levels compared to being in the middle tertile: a mean decrease in 0.067 OD (99% CI -0.122 , 0.012) for Ag85A IgG, 0.057 OD (99% CI -0.105 , -0.009) for PPD IgG and 0.107 (99% CI -0.194 , 0.019) for LAM

L. Stockdale *et al.* **HIV, HCMV and mycobacterial antibody levels****Table 2** Multivariable linear regression of variables with a potential influence on mycobacterial antibody levels. Values obtained using a multivariable regression model including age, quadratic age, sex, HIV and TB status, with *P* values and 99% CI (*n* = 1956)

Variable	<i>n</i> (%)	Ag85A IgG OD		PPD IgG OD		LAM IgG OD		CFP10 ESAT 6 IgG OD		Ag85A IgM OD	
		Coeff (99% CI)	<i>P</i> value	Coeff (99% CI)	<i>P</i> value	Coeff (99% CI)	<i>P</i> value	Coeff (99% CI)	<i>P</i> value	Coeff (99% CI)	<i>P</i> value
Sex											
Male	978/1956 (50.0%)	Baseline		Baseline		Baseline		Baseline		Baseline	
Female	978/1956 (50.0%)	-0.002 (-0.045, 0.041)	0.9	-0.002 (-0.042, 0.038)	0.91	-0.017 (-0.099, 0.064)	0.58	-0.025 (-0.083, 0.033)	0.27	-0.012 (-0.103, 0.079)	0.73
HCMV tertiles											
HCMV low	650/1956 (33.2%)	-0.037 (-0.090, 0.016)	0.07	-0.009 (-0.051, 0.033)	0.57	-0.061 (-0.151, 0.030)	0.08	-0.100 (-0.156, -0.044)	<0.001	-0.104 (-0.205, -0.004)	0.01
HCMV medium	650/1956 (33.2%)	Baseline		Baseline		Baseline		Baseline		Baseline	
HCMV high	656/1956 (33.5%)	-0.067 (-0.122, -0.012)	<0.001	-0.057 (-0.105, -0.009)	<0.001	-0.107 (-0.194, -0.019)	<0.001	-0.015 (-0.077, 0.047)	0.54	-0.058 (-0.152, 0.035)	0.11
HIV status											
Negative	1860/1956 (95.1%)	Baseline		Baseline		Baseline		Baseline		Baseline	
Positive	96/1956 (4.9%)	-0.240 (-0.361, -0.119)	<0.001	-0.310 (-0.422, -0.198)	<0.001	-0.420 (-0.586, -0.253)	<0.001	-0.266 (-0.409, -0.123)	<0.001	-0.446 (-0.640, -0.251)	<0.001
TB status											
Negative	1929/1956 (98.6%)	Baseline		Baseline		Baseline		Baseline		Baseline	
Positive	27/1956 (1.4%)	-0.101 (-0.322, 0.121)	0.24	-0.035 (-0.217, 0.147)	0.62	0.158 (-0.107, 0.424)	0.13	0.175 (-0.241, 0.590)	0.28	-0.135 (-0.609, 0.340)	0.46

L. Stockdale *et al.* HIV, HCMV and mycobacterial antibody levels**Table 3** Multivariable linear regression of variables with a potential influence on total IgG and TT-specific IgG levels. Values obtained using a multivariable regression model including age, quadratic age, sex, HIV and TB status, with *P* value and 99% CI (*n* = 1956)

Variable	<i>n</i> (%)	Total IgG (g/l)		TT IgG OD	
		Coeff (99% CI)	<i>P</i> value	Coeff (99% CI)	<i>P</i> value
Sex					
Male	978/1956 (50.0%)	Baseline		Baseline	
Female	978/1956 (50.0%)	-0.326 (-2.350, 1.697)	0.68	0.272 (0.188, 0.356)	<0.001
HCMV tertiles					
HCMV low	650/1956 (33.2%)	0.318 (-2.240, 2.877)	0.75	-0.090 (-0.187, 0.008)	0.02
HCMV medium	650/1956 (33.2%)	Baseline		Baseline	
HCMV high	656/1956 (33.5%)	0.915 (-1.508, 3.338)	0.33	0.065 (-0.029, 0.159)	0.08
HIV status					
Negative	1860/1956 (95.1%)	Baseline		Baseline	
Positive	96/1956 (4.9%)	9.110 (3.735, 14.485)	<0.001	-0.172 (-0.357, 0.012)	0.02
TB status					
Negative	1929/1956 (98.6%)	Baseline		Baseline	
Positive	27/1956 (1.4%)	-5.789 (-13.298, 1.720)	0.05	-0.081 (-0.328, 0.165)	0.4

CI, confidence interval; OD, optical density.

IgG (all *P* < 0.001, Table 2). While the direction of change was the same for CFP10/ESAT6 IgG and Ag85A IgM, the mean decrease associated with being in the upper tertile of HCMV IgG response was not sufficiently large to provide good evidence of a difference based upon our significance threshold (Table 2). The association between mycobacterial antibody levels and magnitude of HCMV IgG response was not linear (Figure 3): in comparison to the middle tertile of HCMV IgG response, the lowest tertile was also associated with a decrease in mycobacterial antibody levels. A mean decrease of 0.100 OD (99% CI -0.156, -0.044) *P* < 0.001 was seen for CFP10/ESAT6 IgG and a mean decrease of 0.104 OD (99% CI -0.205, -0.004) *P* = 0.01 for Ag85A IgM. The direction of change was the same for the remaining mycobacterial antibodies (Table 2).

Being a sputum-confirmed active TB case was not associated with any differences in any mycobacterial antibody level after adjusting for age, sex, HIV and HCMV level, although given that there were only 27 cases, there was limited statistical power to detect associations (Table 2). Coefficients of the effect of HIV and HCMV for each outcome measurement were similar for a model including BCG instead of TB, and the magnitude of effect was not altered by adjusting for total IgG. Being BCG vaccinated was associated with a 0.115 OD increase in TT IgG (99% CI 0.004–0.227) *P* = 0.01.

Table 3 shows that HIV positivity was associated with an increase in total levels of IgG (9.110 g/l (99% CI 3.735, 14.485), *P* < 0.001). Being female was associated with an increase in TT of 0.272 OD (99% CI 0.188, 0.356, *P* < 0.001) but no difference in total IgG levels.

While being an active TB case was not associated with any differences in TT IgG, being a TB case was associated with a 5.8 g/l decrease (99% CI -13.298, 1.720) in total IgG however this was not significant (*P* = 0.05). The magnitude of HCMV IgG response did not affect either total IgG levels or TT IgG response (Table 3).

Discussion

In this study, we found that HIV infected individuals had decreased levels of all mycobacterial antibodies studied, with a concomitant increase in total IgG. We also found that individuals with the highest levels of HCMV IgG (indicative of highest exposure [26, 27]), had decreased levels of IgG specific for Ag85A, PPD and LAM, but had no corresponding change in total IgG levels. Previously our group has shown that TB patients have increased levels of HCMV IgG [17] and that HCMV positive infants (as measured by HCMV IFN- γ ELISPOT) were at higher risk of progressing to active TB disease [13]. HCMV infection, being linked to poor long-term health outcomes [28, 29] and large immune system subversion [16, 30], may be acting to manipulate mycobacterial antibodies which may be contributing to protective mechanisms against *M.tb* infection.

As has been seen previously [31], humoral responses against RD1 antigens ESAT6 or CFP10 (mycobacterial proteins associated specifically with *M.tb* and not NTM or BCG) did not show an association with active TB cases in this study. Due to a lack of active TB case-finding in the GPC, it is likely that some of the individuals classed as TB negative here were latently infected with




Figure 3 Adjusted mean OD change associated with HCMV tertile comparing to medium HCMV tertile as baseline. *P* values from multivariable linear regression model including age, quadratic age, sex, HIV and TB. Total $n = 1956$. Vertical lines show 99% CI for each mean OD change. CI, confidence interval, OD, optical density (*model includes, age, quadratic age, sex, HIV and TB).

M.tb based on epidemiologic data on exposure in Uganda [32, 33]. The finding that IgG responses to these *M.tb*-specific antigens increase with age, following a similar pattern as other non-*M.tb*-specific mycobacterial antibodies, suggests that while NTM may be driving high responses of acute (IgM) and sustained (IgG) mycobacterial responses, exposure to *M.tb* itself cannot be ignored.

BCG vaccine status allocation in this study was by the presence of scar, inspection of immunisation card or verbal confirmation by parent of guardian. Despite issues with these methods [34], classification was thought to be robust due to the evidence of association of TT IgG with BCG indicating that people vaccinated for one Extended Programme of Immunization (EPI) schedule vaccine are more likely to have received other vaccinations upon accessing local health centres.

The magnitude of difference in mycobacterial antibodies seen due to HIV infection was far greater than due to either active TB disease or BCG vaccination. The lower levels of mycobacterial antibodies seen in individuals

infected with HIV is accompanied by an increase in total IgG. The effect seen here points towards HIV infection having a mycobacteria-specific effect as opposed to a more general depression of all antibody levels, thereby confirming evidence seen previously in a much smaller number of patients in Italy [35]. It is known that HIV preferentially depletes TB-specific CD4 T cells [36]. Through their absence, TB-specific T cells would not provide signals to B cells in order for them to proliferate and differentiate into immunoglobulin-secreting plasma cells. As far as we are aware, the possible downstream humoral mechanism of HIV-associated TB-specific T-cell depletion has not been investigated.

Here we see a similar association between the highest levels of HCMV IgG, and decreased levels of some mycobacterial antibodies. This is not accompanied by a decrease in total IgG or TT IgG. As a human herpes virus, HCMV persists in a variety of cell types in a dormant state and is transmitted through body fluids [37]. Infection is not normally associated with symptomatic

disease; however, it poses a huge burden on the immune system, with maintenance of up to 30% of both CD4 and CD8 circulating memory T cells being specific to HCMV [38]. The virus is a significant factor in immune variation [16], immunosenescence [15] and causes immune activation [39], including non-specific polyclonal B-cell activation and proliferation [40].

In this study, we see decreased mycobacterial antibody levels at both HCMV IgG extremes among HCMV seropositive individuals. Evidence of HCMV effect on vaccine responses exists, showing both a detrimental impact of HCMV infection [41, 42] and a positive, 'adjuvanting', effect of HCMV on vaccine-induced antibody responses in humans [43]. Given reports that cellular responses to heterologous virus challenge in mice may depend on the initial viral dose of HCMV [44, 45] the lack of a linear response between HCMV IgG and mycobacterial antibody levels seen in this study may also be indicative of different effects at different HCMV exposure levels. PBMC samples were not available from this cohort for us to determine if the magnitude of HCMV IgG level had a similar impact on the mycobacteria-specific cellular immune response. However, it is likely that cellular immunity is also impacted by HCMV given that HCMV has been shown to affect both humoral and cell-mediated immune responses to vaccine antigens [46, 47].

Before the widespread use of highly active anti-retrovirals (HAART), HCMV/HIV co-infection saw HCMV as an important cause of severe non-AIDS events, including death, in HIV-infected individuals [48]. High levels of HCMV IgG, caused by repeated reactivation or reinfection events, are associated with higher all-cause mortality [49] and lower CD4 cell count, with accompanying worse response to anti-retrovirals [50]. Despite literature describing HCMV-induced B-cell activation [40, 51, 52], in this study we saw no relationship between HCMV exposure and increased levels of total IgG. We do however see a trend towards decreased mycobacterial antibody response in individuals with very high HCMV IgG responses after adjusting for HIV infection. Considering the risk of developing active TB disease increases over 20 times in individuals with HIV [53], it is likely that any added effect of HCMV would be masked. The mycobacterial antibody-specific decrease seen with both HIV infection and, independently, in the highest tertile of HCMV exposure, may be indicative of a functional, protective role of mycobacterial-specific antibodies which are independently decreased by HIV and high levels of exposure to HCMV.

In summary, both HIV infection and high levels of HCMV IgG were both associated with decreases in mycobacterial antibody levels. Given this novel finding of

effect of HCMV exposure on mycobacterial antibody levels, investigation of magnitude of HCMV may be important in future TB clinical trials to understand the immune environment, independently of HIV infection status. In addition to quantification of antibody levels, we believe that it will be important to measure HCMV effect on mycobacteria-specific cellular responses. A more nuanced understanding of the quality, as well as the quantity, of the mycobacterial antibodies elicited, in terms of antibody class, subtype and avidity may help to shed light upon a potential mechanism by which they might confer protection to host cells.

Due to insufficient volumes of sera, we were unable to investigate HCMV viral load in serum samples to ascertain whether active infection at point of blood draw was associated with any of the measurements taken for this study. Despite this, we believe that the use of HCMV-specific IgG is a robust a measure of cumulative exposure. As previously mentioned, active TB case finding is not carried out within the GPC and therefore we cannot be sure that some individuals analysed as 'non-TB' are not latently infected. PBMC samples were not available from this cohort for us to determine if HCMV had a similar impact on the mycobacterial cellular immune response.

Acknowledgements

We thank all GPC participants and their families. S. Malikaarjun (Otsuka Pharmaceutical Development and Commercialization, Inc, USA) for critical reading of the manuscript, and D. Veerabadran (Aeras, Maryland, USA) for the gift of PPD and recombinant Ag85A. The Ugandan General Population Cohort study is jointly funded by the UK Medical Research Council (MRC) and the UK Department for International Development (DFID) under the MRC/DFID Concordat agreement. This work was supported by Aeras, Rockville, MD, USA and a UK Medical Research Council studentship for LS [grant number MR/J003999/1] and Medical Research Council funding for SN [grant number MR/K012126/1]. HF received support for this project from EC HORIZON2020 TBVAC2020 [grant number 643381].

References

1. Li H, Javid B. Antibodies and tuberculosis: finally coming of age? *Nat Rev Immunol* 2018; 18: 1–6.
2. Keane J, Gershon S, Wise R *et al.* Tuberculosis associated with infliximab, a tumor necrosis factor α -neutralising agent. *N Engl J Med* 2001; 345: 1098.
3. Dorman SE, Holland SM. Mutation in the signal-transducing chain of the interferon- γ receptor and susceptibility to

L. Stockdale *et al.* **HIV, HCMV and mycobacterial antibody levels**

- mycobacterial infection. *J Clin Invest* 1998; **101**: 2364–2369.
4. Kagina BMN, Abel B, Scriba TJ *et al.* Specific T cell frequency and cytokine expression profile do not correlate with protection against tuberculosis after bacillus Calmette-Guérin vaccination of newborns. *Am J Respir Crit Care Med* 2010; **182**: 1073–1079.
 5. Tameris MD, Hatherill M, Landry BS *et al.* Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. *Lancet* 2013; **381**: 1021–1028.
 6. Pamer EG. Immune responses to *Listeria monocytogenes*. *Nat Rev Immunol* 2004; **4**: 812–823.
 7. MacLennan CA. Antibodies and protection against invasive salmonella disease. *Front Immunol* 2014; **5**: 1–4.
 8. Fletcher HA, Snowden MA, Landry B *et al.* T-cell activation is an immune correlate of risk in BCG-vaccinated infants from the MVA85A efficacy trial. *Nat Commun* 2016; **7**: 1–10.
 9. Sánchez-Rodríguez C, Estrada-Chávez C, García-Vigil J *et al.* An IgG antibody response to the antigen 85 complex is associated with good outcome in Mexican Totonaca Indians with pulmonary tuberculosis. *Int J Tuberc Lung Dis* 2002; **6**: 706–712.
 10. Diedrich CR, Flynn JL. HIV-1/Mycobacterium tuberculosis coinfection immunology: How does HIV-1 exacerbate tuberculosis? *Infect Immun* 2011; **79**: 1407–1417.
 11. Wu P-H, Lin Y-T, Hsieh K-P, Chuang H-Y, Sheu C-C. Hepatitis C virus infection is associated with an increased risk of active tuberculosis disease: a nationwide population-based study. *Medicine (Baltimore)* 2015; **94**: e1328.
 12. Walaza S, Tempia S, Dawood H *et al.* Influenza virus infection is associated with increased risk of death amongst patients hospitalized with confirmed pulmonary tuberculosis in South Africa, 2010–2011. *BMC Infect Dis* 2015; **15**: 26.
 13. Muller J, Matsumiya M, Snowden MA *et al.* Cytomegalovirus infection is a risk factor for TB disease in Infants. bioRxiv 2017.
 14. van de Berg PJ, Heutinck KM, Raabe R *et al.* Human cytomegalovirus induces systemic immune activation characterized by a type 1 cytokine signature. *J Infect Dis* 2010; **202**: 690–699.
 15. Almanzar G, Schwaiger S, Jenewein B *et al.* Long-term cytomegalovirus infection leads to significant changes in the composition of the CD8 + T-cell repertoire, which may be the basis for an imbalance in the cytokine production profile in elderly persons. *J Virol* 2005; **79**: 3675–3683.
 16. Brodin P, Jovic V, Gao T *et al.* Variation in the human immune system is largely driven by non-heritable influences. *Cell* 2015; **160**: 37–47.
 17. Stockdale L, Nash S, Nalwoga A *et al.* Human cytomegalovirus epidemiology and relationship to cardiovascular and tuberculosis disease risk factors in a rural Ugandan cohort. *PLoS ONE* 2018; **13**: e0192086.
 18. Olalaye OD, Omilabu SA, Baba SS. Cytomegalovirus infection among tuberculosis patients in a chest hospital in Nigeria. *Comp Immun Microbiol Infect Dis* 1990; **13**: 101–106.
 19. Sirenko I, Shmat'ko S, Smelianskaia M, Peremot S, Marchenko OI, Podoprigora N. Impact of cytomegalovirus infection on the course of tuberculosis in children and adolescents. *Probl Tuberk Bolezn Legk* 2003; **8**: 7–9.
 20. Costello AML, Kumar A, Narayan V *et al.* Does antibody to mycobacterial antigens, including lipoarabinomannan, limit dissemination in childhood tuberculosis? *Trans R Soc Trop Med Hyg* 1992; **86**: 686–692.
 21. Angala SK, Belardinelli JM, Huc-claustre E, Wheat WH, Jackson M. The cell envelope glycoconjugates of *Mycobacterium tuberculosis*. *Crit Rev Biochem Mol Biol* 2014; **49**: 361–399.
 22. Lenzini L, Rottoli P, Rottoli L. The spectrum of human tuberculosis. *Clin Exp Immunol* 1977; **27**: 230–237.
 23. Millington KA, Fortune SM, Low J, Garces A, Hingley-wilson SM. Rv3615c is a highly immunodominant RD1 (Region of Difference 1) -dependent secreted antigen specific for *Mycobacterium tuberculosis* infection. *PNAS* 2011; **108**: 5730–5735.
 24. Asiki G, Murphy G, Nakiyingi-Miiri J *et al.* The general population cohort in rural southwestern Uganda: a platform for communicable and non-communicable disease studies. *Int J Epidemiol* 2013; **42**: 129–141.
 25. The Republic of Uganda. Uganda national expanded programme on immunization multi year plan 2012–2016. 2012.
 26. Mehta SK, Stowe RP, Feiveson AH, Tyring SK, Pierson DL. Reactivation and shedding of cytomegalovirus in astronauts during spaceflight. *J Infect Dis* 2000; **182**: 1761–1764.
 27. Dollard SC, Keyserling H, Radford K *et al.* Cytomegalovirus viral and antibody correlates in young children. *BMC Res Notes* 2014; **7**: 2–5.
 28. Tarter KD, Simanek AM, Dowd JB, Aiello AE. Persistent viral pathogens and cognitive impairment across the life course in the third national health and nutrition examination survey. *J Infect Dis* 2014; **209**: 837–844.
 29. Bai B, Wang X, Chen E, Zhu H. Human cytomegalovirus infection and colorectal cancer risk: a meta-analysis. *Oncotarget* 2016; **7**: 1–8.
 30. van de Berg PJ, van Stijn A, ten Berge IJ, van Lier RA. A fingerprint left by cytomegalovirus infection in the human T cell compartment. *J Clin Virol* 2008; **41**: 213–217.
 31. Hoff ST, Abebe M, Ravn P *et al.* Evaluation of *Mycobacterium tuberculosis*-specific antibody responses in populations with different levels of exposure from Tanzania, Ethiopia, Brazil, and Denmark. *Clin Infect Dis* 2007; **45**: 575–582.
 32. Nkurunungi G, Lutangira JE, Lule SA *et al.* Determining *Mycobacterium tuberculosis* infection among BCG-immunised Ugandan children by T-SPOT.TB and tuberculin skin testing. *PLoS ONE* 2012; **7**: e47340.
 33. Lule SA, Mawa PA, Nkurunungi G *et al.* Factors associated with tuberculosis infection, and with anti-mycobacterial immune responses, among five year olds BCG-immunised at birth in Entebbe, Uganda. *Vaccine* 2015; **33**: 796–804.
 34. Floyd S, Ponnighaus JM, Bliss L *et al.* BCG scars in northern Malawi: sensitivity and repeatability of scar reading,

L. Stockdale *et al.* **HIV, HCMV and mycobacterial antibody levels**

- and factors affecting scar size. *Int J Tuberc Lung Dis* 2000; **4**: 1133–1142.
35. Saltini C, Amicosante M, Girardi E *et al.* Early abnormalities of the antibody response against *Mycobacterium tuberculosis* in human immunodeficiency virus infection. *J Infect Dis* 1993; **168**: 1409–1414.
 36. Geldmacher C, Ngwenyama N, Schuetz A *et al.* Preferential infection and depletion of *Mycobacterium tuberculosis*-specific CD4 T cells after HIV-1 infection. *J Exp Med* 2010; **207**: 2869–2881.
 37. Kerrey BT, Morrow A, Geraghty S, Huey N, Sapsford A, Schleiss MR. Breast milk as a source for acquisition of cytomegalovirus (HCMV) in a premature infant with sepsis syndrome: detection by real-time PCR. *J Clin Virol* 2006; **35**: 313–316.
 38. Sylwester A, Mitchell B, Edgar J *et al.* Broadly targeted human cytomegalovirus-specific CD4⁺ and CD8⁺ T cells dominate the memory compartments of exposed subjects. *J Exp Med* 2005; **202**: 673–685.
 39. Wittkop L, Bitard J, Lazaro E *et al.* Effect of cytomegalovirus-induced immune response, self antigen-induced immune response, and microbial translocation on chronic immune activation in successfully treated HIV type 1-infected patients: the ANRS CO3 Aquitaine Cohort. *J Infect Dis* 2013; **207**: 622–627.
 40. Hutt-Fletcher LM, Balachandran N, Elkins MH. B cell activation by cytomegalovirus. *J Exp Med* 1983; **158**: 2171–2176.
 41. Chidrawar S, Khan N, Wei W *et al.* Cytomegalovirus-seropositivity has a profound influence on the magnitude of major lymphoid subsets within healthy individuals. *Clin Exp Immunol* 2009; **155**: 423–432.
 42. Trzonkowski P, Myśliwska J, Szmit E *et al.* Association between cytomegalovirus infection, enhanced proinflammatory response and low level of anti-hemagglutinins during the anti-influenza vaccination - An impact of immunosenescence. *Vaccine* 2003; **21**: 3826–3836.
 43. Furman D, Jovic V, Sharma S *et al.* Cytomegalovirus infection improves immune responses to influenza. *Sci Transl Med* 2015; **7**: 1–22.
 44. Redeker A, Remmerswaal EBM, van der Gracht ETI *et al.* The contribution of cytomegalovirus infection to immune senescence is set by the infectious dose. *Front Immunol* 2018; **8**: 1–15.
 45. Redeker A, Welten SPM, Arens R. Viral inoculum dose impacts memory T-cell inflation. *Eur J Immunol* 2014; **44**: 1046–1057.
 46. Theeten H, Mathei C, Peeters K *et al.* Cellular interferon gamma and granzyme B responses to cytomegalovirus-pp65 and influenza N1 are positively associated in elderly. *Viral Immunol* 2016; **29**: 169–175.
 47. Derhovannessian E, Maier AB, Hähnel K, McElhaney JE, Slagboom EP, Pawelec G. Latent infection with cytomegalovirus is associated with poor memory CD4 responses to influenza A core proteins in the elderly. *J Immunol* 2014; **193**: 3624–3631.
 48. Lichtner M, Cicconi P, Vita S, Cozzi-Lepri A, Galli M, Lo Caputo S, ... d'Arminio Monforte A. CMV co-infection is associated with increased risk of severe non-AIDS events in a large cohort of HIV-infected patients. *J Infect Dis* 2015; **211**: 178–186.
 49. Roberts ET, Haan MN, Dowd JB, Aiello AE. Cytomegalovirus antibody levels, inflammation, and mortality among elderly latinos over 9 years of follow-up. *Am J Epidemiol* 2010; **172**: 363–371.
 50. Giuliano M, Pirillo MF, Liotta G *et al.* High CMV IgG antibody levels are associated to a lower CD4⁺ RESPONSE to antiretroviral therapy in HIV-infected women. *J Clin Virol* 2017; **96**: 17–19.
 51. Price PO, Olver SD, Gibbons AE, Shellam GR. B-cell activation following murine cytomegalovirus infection: implications for autoimmunity. *Immunology* 1993; **78**: 14–21.
 52. Dauby N, Kummert C, Lecomte S *et al.* Primary human cytomegalovirus infection induces the expansion of virus-specific activated and atypical memory B cells. *J Infect Dis* 2014; **210**: 1275–1285.
 53. Getahun H, Gunneberg C, Granich R, Nunn P. HIV infection-associated tuberculosis: the epidemiology and the response. *Clin Infect Dis* 2010; **50**: S201–S207.

Corresponding Author Lisa Stockdale, LSHTM, ITD, Keppel St, London WC1E 7HT, UK. Tel.: +44 7766 084322; E-mail: lisa.stockdale@lshtm.ac.uk